Merck recently said that the company's supply of #HPV vaccines to China is increasing year by year and will increase significantly in 2022. Cervical cancer is currently most likely to pass HP

Merck recently said that the company's supply of #HPV vaccines to China is growing year by year and will increase significantly in 2022.

Cervical cancer is currently the most likely cancer to be eliminated at the public health level through comprehensive HPV prevention and treatment measures, and the Chinese people have had a strong demand for HPV vaccines in recent years.

In China, Merck has listed two HPV vaccines: quadrivalent and nine-valent, the quadrivalent HPV vaccine is suitable for women aged 9-45 years, and the nine-valent HPV vaccine is currently the vaccine that covers the largest number of HPV types on the market, but only for women aged 16-26 years. Abroad, Merck's HPV vaccine has more indications, not only in terms of age restrictions, but also in terms of gender, men can also be injected.

According to reports, Merck is currently actively conducting clinical trials to expand the indications for hpvic vaccines in order to cover more age groups and populations and protect the health of more Chinese people.